Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus
- PMID: 36147598
- PMCID: PMC9487636
- DOI: 10.1093/ofid/ofac457
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus
Abstract
Background: We previously showed that anticholinergic (ACH) medications contribute to self-reported neurocognitive impairment (NCI) in elderly people with human immunodeficiency virus (PWH). The current cross-sectional study further evaluated the effect of ACH and sedative drugs on neurocognitive function in PWH who underwent comprehensive neuropsychological evaluation.
Methods: A medication review was performed in PWH enrolled in the prospective Neurocognitive Assessment in Metabolic and Aging Cohort within the Swiss HIV Cohort Study. Neurocognitive functions were analyzed in 5 domains (motor skills, speed of information, attention/working memory, executive functions, and verbal learning memory). The effect of ACH and sedative medications on neurocognitive functioning was evaluated using linear regression models for the continuous (mean z-score) outcome and multivariable logistic regression models for the binary (presence/absence) outcome.
Results: A total of 963 PWH (80% male, 92% Caucasian, 96% virologically suppressed, median age 52) were included. Fourteen percent of participants were prescribed ≥1 ACH medication and 9% were prescribed ≥1 sedative medication. Overall, 40% of participants had NCI. Sedative medication use was associated with impaired attention/verbal learning and ACH medication use with motor skills deficits both in the continuous (mean z-score difference -0.26 to -0.14, P < .001 and P = .06) and binary (odds ratio [OR], ≥1.67; P < .05) models. Their combined use was associated with deficits in overall neurocognitive functions in both models (mean z-score difference -0.12, P = .002 and OR = 1.54, P = .03). These associations were unchanged in a subgroup analysis of participants without depression (n = 824).
Conclusions: Anticholinergic and sedative medications contribute to NCI. Clinicians need to consider these drugs when assessing NCI in PWH.
Keywords: HIV; anticholinergic medication; neuro-HIV; neurocognitive impairment; sedative medication.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
Similar articles
-
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland.PLoS One. 2021 Mar 2;16(3):e0246579. doi: 10.1371/journal.pone.0246579. eCollection 2021. PLoS One. 2021. PMID: 33651794 Free PMC article.
-
Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study.J Antimicrob Chemother. 2022 Feb 2;77(2):492-499. doi: 10.1093/jac/dkab386. J Antimicrob Chemother. 2022. PMID: 34734255 Review.
-
The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland.Int J STD AIDS. 2021 Jul;32(8):729-739. doi: 10.1177/0956462420987434. Epub 2021 Feb 25. Int J STD AIDS. 2021. PMID: 33629882
-
Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland.Open Forum Infect Dis. 2019 Jul 8;6(7):ofz277. doi: 10.1093/ofid/ofz277. eCollection 2019 Jul. Open Forum Infect Dis. 2019. PMID: 31304188 Free PMC article.
-
Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models.Drugs Aging. 2021 Nov;38(11):977-994. doi: 10.1007/s40266-021-00895-x. Epub 2021 Nov 9. Drugs Aging. 2021. PMID: 34751922 Free PMC article.
Cited by
-
Falls in a single brain rehabilitation center: a 3-year retrospective chart review.Front Neurol. 2025 Feb 24;16:1519555. doi: 10.3389/fneur.2025.1519555. eCollection 2025. Front Neurol. 2025. PMID: 40066305 Free PMC article.
-
Risk factors for cognitive decline in persons with HIV.Curr Opin Infect Dis. 2025 Feb 1;38(1):37-43. doi: 10.1097/QCO.0000000000001080. Epub 2024 Dec 6. Curr Opin Infect Dis. 2025. PMID: 39641182 Free PMC article. Review.
References
-
- Wang Y, Liu M, Qingdong L, et al. Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis. Neurology 2020; 95:e2610–21. - PubMed
-
- Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243–50. - PubMed